title: Pharmacogenetic considerations in the treatment of HIV.
abstract: After the introduction of highly active antiretroviral therapy in the 1990s, the perception of the diagnosis of HIV infection gradually shifted from a 'death sentence' to a chronic disease requiring long-term treatment. The host genetic variability has been shown to play a relevant role in both antiretroviral drugs bioavailability and adverse effects susceptibility. Knowledge about pharmacogenetics role in HIV infection treatment has largely increased over the last years, and is reviewed in the present report, as well as future perspectives for the inclusion of pharmacogenetics information in the directing of HIV infection treatment.
authors.affiliation: Graduate Program in Biosciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre, RS, Brazil.
authors.forename: Vanessa S
authors.initials: VS
authors.lastname: Mattevi
authors.affiliation: Graduate Program in Biosciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre, RS, Brazil.
authors.forename: Carmela Fs
authors.initials: CF
authors.lastname: Tagliari
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D000071184:Pharmacogenomic Variants / Q000187:drug effects / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors
keywords: CYP2B6; CYPs; HAART; HIV; HLA; UGT1A1; drug transporters; non-nucleoside reverse transcriptase inhibitors; nucleoside reverse transcriptase inhibitors; protease inhibitors